Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat on September 4, 2025, at 9:45 a.m. ET in New York City.
Investors can access a live webcast of the presentation through Nuvalent's website, where it will remain available for 30 days after the event.
Nuvalent (Nasdaq: NUVL), una societ脿 biofarmaceutica in fase clinica che sviluppa terapie oncologiche mirate, ha annunciato la sua partecipazione alla Cantor Global Healthcare Conference 2025. La dirigenza dell'azienda, tra cui il CEO James Porter, Ph.D., e la CFO Alexandra Balcom, prender脿 parte a un incontro informale il 4 settembre 2025 alle 9:45 ET a New York City.
Gli investitori potranno seguire la presentazione in diretta streaming tramite il sito web di Nuvalent; il webcast rester脿 disponibile per 30 giorni dopo l'evento.
Nuvalent (Nasdaq: NUVL), una compa帽铆a biofarmac茅utica en fase cl铆nica que desarrolla terapias oncol贸gicas dirigidas, ha anunciado su participaci贸n en la Cantor Global Healthcare Conference 2025. La direcci贸n de la empresa, incluyendo al director ejecutivo James Porter, Ph.D., y la directora financiera Alexandra Balcom, participar谩 en una charla informal el 4 de septiembre de 2025 a las 9:45 a.m. ET en la ciudad de Nueva York.
Los inversores podr谩n acceder a una transmisi贸n en directo de la presentaci贸n a trav茅s del sitio web de Nuvalent; el webcast estar谩 disponible durante 30 d铆as despu茅s del evento.
Nuvalent (Nasdaq: NUVL), 響滌爜 頃晹鞝� 臧滊皽鞚� 歆勴枆 欷戩澑 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 旮办梾鞚� Cantor Global Healthcare Conference 2025鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳澑 CEO 鞝滌瀯鞀� 韽劙(Ph.D.)鞕� CFO 鞎岆爥靷半摐霛� 氚滌饯鞚� 2025雲� 9鞗� 4鞚� 鞓れ爠 9鞁� 45攵�(霃欕秬鞁滉皠, ET) 雺挫殨鞁滌棎靹� 雽�雼挫潉 歆勴枆頃╇媹雼�.
韴瀽鞛愲摛鞚� Nuvalent 鞗轨偓鞚错姼毳� 韱淀暣 頂勲爤鞝犿厡鞚挫厴鞚� 鞁ろ櫓 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頃措嫻 鞗轨簮鞀ろ姼電� 頄夓偓 頉� 30鞚缄皠 鞚挫毄 臧�電ロ暕雼堧嫟.
Nuvalent (Nasdaq: NUVL), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des th茅rapies cibl茅es contre le cancer, a annonc茅 sa participation 脿 la Cantor Global Healthcare Conference 2025. La direction de l'entreprise, notamment le PDG James Porter, Ph.D., et la directrice financi猫re Alexandra Balcom, participera 脿 une discussion informelle le 4 septembre 2025 脿 9h45 (ET) 脿 New York City.
Les investisseurs pourront suivre la pr茅sentation en webcast en direct sur le site web de Nuvalent ; le replay restera disponible pendant 30 jours apr猫s l'茅v茅nement.
Nuvalent (Nasdaq: NUVL), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das zielgerichtete Krebs颅therapien entwickelt, hat seine Teilnahme an der Cantor Global Healthcare Conference 2025 angek眉ndigt. Die Unternehmensf眉hrung, darunter CEO James Porter, Ph.D., und CFO Alexandra Balcom, wird am 4. September 2025 um 9:45 Uhr ET in New York City an einem Gespr盲ch teilnehmen.
Investoren k枚nnen die Pr盲sentation als Live-Webcast 眉ber die Website von Nuvalent verfolgen; der Webcast steht f眉r 30 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
A live webcast will be available in the Investors section of the company's website at聽, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating聽precisely聽targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:
SOURCE Nuvalent, Inc.
FAQ
When is Nuvalent (NUVL) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent Nuvalent at the Cantor Global Healthcare Conference 2025?
How can investors access Nuvalent's presentation at the Cantor conference?
What type of company is Nuvalent (NUVL)?
